127 related articles for article (PubMed ID: 25631751)
1. Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.
Jones RM; Morgan C; Bertelli G
Tumour Biol; 2015 Jun; 36(6):4861-9. PubMed ID: 25631751
[TBL] [Abstract][Full Text] [Related]
2. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
3. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Varol U; Degirmenci M; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Sanli UA; Uslu R
Tumour Biol; 2015 Feb; 36(2):779-86. PubMed ID: 25293519
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Fabbri F; Brigliadori G; Carloni S; Ulivi P; Vannini I; Tesei A; Silvestrini R; Amadori D; Zoli W
J Transl Med; 2008 Aug; 6():43. PubMed ID: 18691406
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.
Coxon JP; Oades GM; Kirby RS; Colston KW
BJU Int; 2004 Jul; 94(1):164-70. PubMed ID: 15217454
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
9. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
12. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Ural AU; Avcu F
Acta Oncol; 2006; 45(4):491-2. PubMed ID: 16760189
[No Abstract] [Full Text] [Related]
13. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Morgan TM; Pitts TE; Gross TS; Poliachik SL; Vessella RL; Corey E
Prostate; 2008 Jun; 68(8):861-71. PubMed ID: 18361409
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
16. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
Zhang P; Wen F; Fu P; Yang Y; Li Q
Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424
[TBL] [Abstract][Full Text] [Related]
17. The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.
Xie F; Li P; Gong J; Zhang J; Ma J
Biochem Biophys Res Commun; 2015 Nov; 467(4):664-9. PubMed ID: 26498526
[TBL] [Abstract][Full Text] [Related]
18. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Witters LM; Crispino J; Fraterrigo T; Green J; Lipton A
Am J Clin Oncol; 2003 Aug; 26(4):S92-7. PubMed ID: 12902864
[TBL] [Abstract][Full Text] [Related]
19. [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].
Zhang ZY; Zhou LQ; Ding Y; Yang L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):959-61. PubMed ID: 20646644
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
